Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: The Indiana University experience

Brachytherapy

Volumn 9, Issue 1, 2010, Pages 61-65

  Fakiris, Achilles J ^a   Henderson, Mark ^a   Lo, Simon S ^b   Look, Katherine Y ^a   Cardenes, Higinia R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORUS 32; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; SALPINGOOOPHORECTOMY; SCAR FORMATION; TREATMENT DURATION; TREATMENT OUTCOME; UTERUS CARCINOMA;

ACADEMIC MEDICAL CENTERS; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOMA, PAPILLARY; FEMALE; HUMANS; INDIANA; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; PHOSPHORUS RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 72449208575     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.10.005     Document Type: Article

References (39)

1. American Cancer Society. Cancer facts & figures 2007 (2007), American Cancer Society, Atlanta, GA
2. Cirisano Jr. F.D., Robboy S.J., Dodge R.K., et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77 (2000) 55-65
3. Hendrickson M., Ross J., Eifel P., Martinez A., et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6 (1982) 93-108
4. Nicklin J.L., and Copeland L.J. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin Obstet Gynecol 39 (1996) 686-695
5. Gehrig P.A., Groben P.A., Fowler W.C., et al. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol 97 (2001) 153-157
6. Slomovitz B.M., Burke T.W., Eifel P.J., et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91 (2003) 463-469
7. Sood B.M., Jones J., Gupta S., et al. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 57 (2003) 208-216
8. Sutton G.P., Brill L., Michael H., et al. Malignant papillary lesions of the endometrium. Gynecol Oncol 27 (1987) 294-304
9. Ward B.G., Wright R.G., and Free K. Papillary carcinomas of the endometrium. Gynecol Oncol 39 (1990) 347-351
10. Geisler J.P., Geisler H.E., Melton M.E., et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma?. Gynecol Oncol 74 (1999) 465-467
11. Bristow R.E., Asrari F., Trimble E.L., et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol 81 (2001) 279-286
12. Goff B.A., Kato D., Schmidt R.A., et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54 (1994) 264-268
13. Bancher-Todesca D., Neunteufel W., Williams K.E., et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 71 (1998) 344-347
14. Gitsch G., Friedlander M.L., Wain G.V., et al. Uterine papillary serous carcinoma. A clinical study. Cancer 75 (1995) 2239-2243
15. Huh W.K., Powell M., Leath C.A., et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 91 (2003) 470-475
16. Tay E.H., and Ward B.G. The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing?. Int J Gynecol Cancer 9 (1999) 463-469
17. Sutton G., Axelrod J.H., Bundy B.N., et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 97 (2005) 755-763
18. Sutton G., Axelrod J.H., Bundy B.N., et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 100 (2006) 349-354
19. Randall M.E., Filiaci V.L., Muss H., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24 (2006) 36-44
20. Soper J.T., Berchuck A., Dodge R., et al. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. Obstet Gynecol 79 (1992) 993-997
21. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322 (1990) 1021-1027
22. Creasman W.T., Disaia P.J., Blessing J., et al. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 141 (1981) 921-929
23. Soper J.T., Creasman W.T., Clarke-Pearson D.L., et al. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol 153 (1985) 191-196
24. Fakiris A.J., Moore D.H., Reddy S.R., et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol Oncol 96 (2005) 818-823
25. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355 (2000) 1404-1411
26. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
27. Scholten A.N., van Putten W.L., Beerman H., et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63 (2005) 834-838
28. McCormick T.C., Cardenes H., and Randall M.E. Early-stage endometrial cancer: is intravaginal radiation therapy alone sufficient therapy?. Brachytherapy 1 (2002) 61-65
29. Grice J., Ek M., Greer B., et al. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients. Gynecol Oncol 69 (1998) 69-73
30. Mehta N., Yamada S.D., Rotmensch J., et al. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 57 (2003) 1004-1009
31. Kato D.T., Ferry J.A., Goodman A., et al. Uterine papillary serous carcinoma (UPSC): A clinicopathologic study of 30 cases. Gynecol Oncol 59 (1995) 384-389
32. Jeffrey J.F., Krepart G.V., and Lotocki R.J. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol 67 (1986) 670-674
33. Gibbons S., Martinez A., Schray M., et al. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 21 (1991) 1019-1025
34. Lim P., Al Kushi A., Gilks B., et al. Early stage uterine papillary serous carcinoma of the endometrium: Effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 91 (2001) 752-757
35. Mallipeddi P., Kapp D.S., and Teng N.N. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer 71 (1993) 3076-3081
36. Smith R.S., Kapp D.S., Chen Q., et al. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys 48 (2000) 767-778
37. Klaassen D., Shelley W., Starreveld A., et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 6 (1988) 1254-1263
38. Klaassen D., Starreveld A., Shelly W., et al. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. A National Cancer Institute of Canada Clinical Trials Group Report. Int J Radiat Oncol Biol Phys 11 (1985) 1801-1804
39. Varia M.A., Stehman F.B., Bundy B.N., et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 2849-2855